Drug Profile
Butyrylcholinesterase - Qrono
Alternative Names: Butyrylcholinesterase Qx; QR 205Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Qrono
- Class Antidotes; Cholinesterases
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Unspecified
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified in USA (Parenteral, Injection)
- 04 Aug 2017 Butyrylcholinesterase- Qrono is available for licensing as of 04 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
- 04 Aug 2017 Clinical trials in Undefined indication in USA (Parenteral) (Qrono pipeline, August 2017)